Please assess the completion status of the following clinical trial:

Trial Title: Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Consistent treatment for chronic, non-cancer-related pain with any full agonist opioid for at least 30 days prior to screening.~* Diagnosis of opioid-induced bowel dysfunction (OBD) as confirmed during the screening period.~* If patient has a history of chronic constipation, condition must have been exacerbated by initiation of opioid treatment.~* Use of prescribed or Over-the-Counter (OTC) medication that affects gastrointestinal motility (other than opioid therapy) must be discontinued during the study.~* If treated for clinical depression with Selective serotonin reuptake inhibitor (SSRIs), Serotonin-norepinephrine reuptake inhibitor (SNRIs), or Monoamine oxidase inhibitor (MAO) inhibitors, treatment must have been at a stable dose for at least 30 days prior to screening.~* Use of laxative and stool softeners (with the exception of approved rescue medications) must be discontinued while on study.~Exclusion Criteria:~* Treatment with opioid therapy for cancer-related pain, abdominal pain, scleroderma, and/or for the management of drug addiction.~* Patient has been treated for cancer in the past 5 years (with the exception of localized basal cell, squamous cell skin cancer, or in situ cancer that has been resected).~* Opioid dose adjustment (+/- 30%), and/or change in opioid agent or route of administration within 30 days of screening.~* Gastrointestinal or abdominal surgical procedures within 90 days prior to screening.~* Non-ambulatory patients, or those who are unable to eat/drink, take oral medications, or to hold down oral medications due to vomiting.~* Female patients of childbearing potential who are unable/unwilling to use protocol-specified method(s) of birth control and/or are pregnant, nursing, or plan to become pregnant or nurse during the study.~* Prior use of Amitiza, lubiprostone, SPI-0211, or RU-0211.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 0 mcg capsules twice daily (BID)
- Lubiprostone (Type: EXPERIMENTAL): 24 mcg capsules twice daily (BID)

Based on this trial design, predict the completion outcome and termination type (if applicable).